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Abstract
Background: MSM are at higher risk for invasive anal cancer. Twelve human papillomaviruses (HPVs) cause cervical cancer in
women (Group 1 high-risk HPVs (hrHPVs)) and 13 HPVs are probable/possible causes (Group 2 hrHPVs) of cervical
malignancy. HPVs rarely associated with malignancy are classified as lower-risk HPVs (lrHPVs).
Materials and Methods: Dacron-swab anal-cytology specimens were collected from and data complete for 97% (1262/
1296) of Multicenter AIDS Cohort Study (MACS) men tested for HPVs using the Linear Array assay. Multivariate Poisson
regression analyses estimated adjusted prevalence ratios for Group 1/2 hrHPVs and lrHPVs, controlling for the effects of age,
race, ethnicity, sexual partnerships, smoking; HIV-infection characteristics, treatment, and immune status among HIV-
infected men.
Results: HIV-infected men showed 35–90% higher prevalence of Group 1/2 hrHPVs and lrHPVs than HIV-uninfected men,
and higher prevalence of multi-Type, and multiple risk-group infections. CD4+ T-cell count was inversely associated with
HPV Group 2 prevalence (p,0.0001). The number of receptive anal intercourse (RAI) partners reported in the 24 months
preceding HPV testing predicted higher prevalence of Group 1/2 hrHPVs. Men reporting $30 lifetime male sex partners
before their first MACS visit and men reporting $1 RAI partners during the 24 months before HPV testing showed 17–24%
and 13–17% higher prevalence of lrHPVs (p-values #0.05). Men reporting smoking between MACS visit 1 and 24 months
before HPV testing showed 1.2-fold higher prevalence of Group 2 hrHPVs (p = 0.03). Both complete adherence to CART
(p= 0.02) and HIV load ,50 copies/mL (p= 0.04) were protective for Group 1 hrHPVs among HIV-infected men.
Conclusions: HIV-infected men more often show multi-type and multi-group HPV infections HIV-uninfected men. Long-
term mutual monogamy and smoking cessation, generally, and CART-adherence that promotes (HIV) viremia control and
prevents immunosuppression, specifically among HIV-infected MSM, are important prevention strategies for HPV infections
that are relevant to anal cancer.
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Introduction
Invasive anal cancer (IAC) is a health crisis for gay, bisexual,
and other men who have sex with men (MSM). Overall, IAC rates
have increased steadily among U.S. men between 1975–2008, but
risk among HIV-infected MSM has increased greatly since the
introduction of combined antiretroviral therapy (CART) for HIV
infection in the late 1990 s [1–5]. Current domestic IAC incidence
estimates among MSM surpass contemporary invasive cervical
cancer rates in women as well as rates reported when domestic
mass cervical cytology screening was initiated in the 1950 s [2,4,6–
11]. Currently, domestic IAC incidence rates among HIV-infected
MSM surpass rates for 7 of the top 10 cancers, 13–36 cases/
100,000, and even exceeds the third most common cancer,
colorectal cancer, for all U.S. males: conservatively, 78 vs. 53/
100,000, respectively [1,2,4,12,13].
Human papillomaviruses (HPVs) infect epithelial cells and show
varying degrees of pathogenicity from warts to invasive cancers.
Until recently, 14 viruses were referred to as high-risk HPVs
(hrHPVs): HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68,
and 69 [14,15]. Currently, the first 12 are classified as Group 1
hrHPVs, and considered necessary but insufficient causes of
cervical cancer by the International Agency for Research on
Cancer (IARC) [14]. Among these, HPV16 is considered most
pathogenic and is detected most often in cancers [14]. Experts
generally agree that most Group 1 hrHPVs are strong carcinogens
[16]. Additionally, IARC recently regrouped HPV68 and 69,
together with 11 other viruses, HPV26, 30, 34, 53, 66, 67, 70, 73,
82, 85, and 97 as probable or possible, weaker carcinogens,
collectively evaluated as Group 2 hrHPVs [14,16]. Low-grade
dysplasias, such as genital warts, are commonly caused by HPVs
that are seldomly associated with cancers. Lower-risk HPV
(lrHPV) Types 6, 11, 40, 42, 54, 55, 61, 62, 64, 71, 72, 81, 83,
84, Is39, and CP6108 can be simultaneously characterized with
Group 1 and 2 hrHPVs using PCR and dot-blot hybridization
(HPV-Linear Array (HPV-LA), Roche Diagnostics, Pleasanton,
CA) [17–19]. However, the HPV-LA assay only evaluates HPV26,
53, 66, 67, 68, 69, 70, 73, and 82 Group 2 hrHPVs, but not
HPV30, 34, 85, and 97 [17–19].
Anal-genital HPV prevalence estimates for men vary widely,
over time and across studies, and methodological differences make
it difficult to compare findings across these groups [20–22]. No
published study evaluates the HPV-infection characteristics in a
well-described population of HIV-infected and -uninfected MSM
50 years or older who are likely to be at highest risk for anal cancer
[2,20,23,24], and little is known about the effect of HIV-treatment
adherence on HPV infection in affected MSM [25]. Additionally,
no studies yet evaluate sociodemographic and behavioral risk
factors for Group 1 and 2 hrHPVs separately using International
Agency for Research on Cancer (IARC) risk groupings [14].
Accordingly, data for 1,262 well-described Multicenter AIDS
Cohort Study (MACS) participants were evaluated to test the
hypotheses that age, and other social and demographic charac-
teristics, and longitudinally-reported sexual behaviors positively
affected Group 1 and 2 hrHPV and lrHPV prevalence, while
HIV-treatment and some –infection characteristics differentially
influence the prevalence of hr- and lrHPVs.
Materials and Methods
Subjects and Setting
The Anal Health Study was approved locally at each of 4
U.S. MACS study sites: IRB#:84-03-02-01-1 (Baltimore) ap-
proved by the Johns Hopkins Bloomberg School of Public Health
Institutional Review Board (IRB), 01–225/CR3-STU00022906
(Chicago) approved by the Northwestern University IRB, 10-
001677-CR-00002/103360-11 (Los Angeles) approved by the
UCLA IRB, and REN12070132/IRB9505118 (Pittsburgh) ap-
proved by the University of Pittsburgh IRB. Men were invited by
research personnel to participate in the AHS at the first MACS
visit following the study’s opening in May 2010. Written informed
consent for anal Pap test and HPV genotyping was obtained and
study specimens were collected for 1,296 MSM at the first AHS
study visit completed between May 2010 and February 2011. Of
these, data were complete and HPV assays were interpretable for
97.3% (1262/1296). The MACS is described extensively else-
where [26–28]. Briefly, 2,291 men were in active follow-up as of
March 31, 2012:61% (1389/2291) were enrolled before 2001 and
49% (1131/2291) were HIV-infected. Since the mid-1990 s, the
study aims focus on describing the natural history of HIV-infection
in the treatment era [26]. MACS participants are examined semi-
annually using standard protocols by trained examiners and
demographic, general health, neuro-cognitive, sexual and behav-
ioral characteristics are collected using both interviewer-guided
and self-administered questionnaires. Laboratory specimens are
gathered and preserved or tested semi-annually using standard
MACS protocols; for example, only sera for men testing negative
at the prior study visit are evaluated for HIV antibody using
enzyme-lined immunosorbant assays and western blot [27].
Exposures of Interest
Demographic, sexual, behavioral, and HIV-infection charac-
teristics and HIV-related laboratory estimates for CD4+ T-
lymphocyte counts were evaluated. Data for Black, Asian,
American Indian or Alaskan Native, and other races (non-Whites),
were compared to those of Whites; men reporting Hispanic
ethnicity were compared to non-Hispanics. Sexual exposures were
evaluated using three different measures: 1) the number of lifetime
male sex partners reported at the first MACS visit (.300, 100–
299, 30–99, vs. ,30), 2) the number of male sex partners reported
at each semi-annual study visit between the first MACS visit and
the study visit 24 months before HPV testing (.200, 100–199, 30–
99 vs. ,30), and 3) the number of male receptive anal intercourse
(RAI) partners reported at each of the last four semi-annual visits
preceding the HPV-test visit ($4, 1–3, vs. 0). Men who reported
smoking (tobacco) were compared to never-smokers for two
periods: 1) MACS visit 1 to 24 months before HPV testing and 2)
over the last 24 months before testing. Data for HIV-infected men
with .500, 350–500 and ,350 CD4+ T-cells/mm3 at the HPV
test-visit were compared to those of HIV-uninfected men; for
analyses of HIV-infected men alone, those with .500 CD4+ T-
cells/mm3 served as the referent group. HIV-infection duration
was estimated as the total number of years since enrollment for
prevalent positive men and since HIV-antibodies were detected for
HIV-seroconverters. Multiple measures of HIV-infection control
evaluated optimal versus less optimal HIV-infection treatment and
control: 1) the proportion of total visits where HIV mRNA (HIV-
load) measured #50 copies/mL in serum (Roche Amplicor 2.0,
Roche Molecular Inc., Pleasanton, California), 2) the lowest CD4+
T-cell measurement measured since HIV was first detected by the
MACS (,200 vs. $200 cells/mm3), 3) the number of years of
CART treatment (per year), and 4) self-reported complete
adherence to CART over the 4 days preceding the HPV-test visit
(yes/no). Data for three study sites were compared to the largest
AHS-enrollment site and data for men recruited before 2001 were
compared to men entering thereafter to control for the effects of
geographic variability and time.
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Outcome of Interest
The prevalence of Group 1 and 2 hrHPVs and lrHPVs were
evaluated using residual anal cytology specimens and PCR.
Briefly, anal cytology specimens were collected using a standard
protocol: Dacron swabs were inserted ,5 cm beyond the anal
verge, approximated to the anal wall, rotated slowly while being
withdrawn to capture cells and pathogens, and placed into
preservative (PreservCyt, Cytyc Corporation, Boxborough, MA).
DNA was extracted from residual cytology specimens (AmpiLute
Media Extraction Kit, Qiagen, Valencia, CA) by a single
laboratory (Tricore Reference Laboratory, Albuquerque, New
Mexico). The HPV-LA uses the PGMY09/PGMY11 primers to
characterize the L1 consensus region of HPV DNA (Roche
Diagnostics, Pleasanton, California) [17]. Two concentrations of a
b-globin control probe assessed specimen adequacy and PCR
inhibition. The assay detects up to 37 targeted HPV types with
94.8% sensitivity and 38% specificity for predicting cytological
disease, especially high-grade cervical intraepithelial neoplasia and
invasive cervical cancer [29]. HPV-LA shows high concordance
with findings from other HPV genotyping assays (Kappa = 0.78,
p,0.001) [17,29,30]. Analyses compared group-specific preva-
lence estimates for hr- and lrHPVs: Group 1, strongly carcinogenic
hrHPVs, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59;
Group 2, weakly carcinogenic hrHPVs, HPV26, 53, 66, 67, 68,
69, 70, 73, and 82 (not 30, 34, 85, 97); and lrHPVs, HPV6, 11, 40,
42, 54, 55, 61, 62, 64, 71, 72, 81, 83, 84, Is39, CP6108 [14].
Statistical Analyses
Descriptive and tabular analyses were used to explore the data.
The Fisher exact or the Wilcoxon nonparametric tests, as
appropriate, were used to test differences in proportions and
distributions of characteristics for HIV-infected and HIV-unin-
fected men. For age-group comparisons of prevalence estimates,
the exact 95% confidence intervals were estimated using the
binomial distribution. Poisson regression with robust error
variance [31] analyses were used to estimate prevalence ratios
(PR) and 95% confidence intervals (CI) for Group 1 and 2
hrHPVs, and lrHPVs, comparing demographic, sexual behavioral
characteristics, HIV-infection characteristics, and recruitment
period in both univariate and multivariate models using the SAS
9.2 GENMOD procedure (SAS Institute, Cary, North Carolina,
United States of America). All models included age, race, period-
specific self-reported number of sexual partnerships, HIV-infection
characteristics, and tobacco-smoking. Additionally, comparisons
among HIV-infected men alone also included HIV-infection
duration and -load and -treatment features, and CD4+ count (cell/
mm3) characteristics at the HPV-test visit and the lowest
measurement observed across the observation period.
Results
Descriptive Analyses
The 1,262 participants were predominantly older, White MSM
of whom nearly 80% (1005/1262) tested positive for $1 HPVs.
On average, men were 55 (69.4) years old at the HPV-test visit,
and nearly 68% (859/1262) had joined the study in 2001.
Hispanic ethnicity was reported by 8% (100/1262), and self-report
for race showed 79% (993/1262) were White, and 21% were
minority races (Table 1). Nearly half (46%, 579/1262) were HIV-
infected. However, minority men showed 1.6-fold higher preva-
lence of HIV-infection than White participants: 65% (59%, 70%)
vs. 41% (38%, 44%), respectively (p,0.001). Only 16% (93/579)
of HIV-infected men reported any prior AIDS-defining illnesses at
the first HPV test visit and while HIV-infected men showed lower
CD4+ T-cell counts than -uninfected men, their levels measured
high, on average, at the HPV-test visit: 609 cells/mm3 vs. 929
cells/mm3, respectively (p,0.05) (Table 1). Over the entire study
period, HIV-infected men showed HIV-load measurements ,50
copies/mL at ,53% of visits; however, the nadir CD4+ T-cell
count observed among these men, on average, was 258 cell/mm3
(Table 1). Smoking most dramatically changed over the course of
the MACS study among HIV-uninfected men. The majority of
participants (72%; 913/1262) reported smoking at least once
between the first MACS visit and the visit 24 months before HPV
testing, HIV-infected men were 1.8-times more likely to report
smoking than –uninfected men during the last 24 months before
HPV testing (Table 1). The number of lifetime male sex partners
reported at the first MACS visit varied widely and the distribution
was skewed right: m= 270 (6488), median (M) = 100), range: 1–
9999+, and 29% (349/1222) reported $300 lifetime partners.
However, nearly 74% (920/1250) of men reported 0–3 RAI
partnerships during the last 24 months before HPV testing.
Overall, HIV-infected men showed 30% higher prevalence of
HPV infection than HIV-uninfected men (PR = 1.3 (1.2, 1.4),
prevalence: 91% (525/579) vs. 70% (480/683), respectively;
Table 1)).
Type and group-specific HPV infection charac-
teristics. Most men tested positive for one or more HPVs;
however, only 25% (319/1262) tested positive for HPV16 or -18
alone or in combination with other HPVs (Table 1). HIV-infected
men showed a higher prevalence of HPV16/18 infection than
HIV-uninfected men: 31% (180/579) vs. 20% (139/683) (Table 1).
Among hrHPVs, HPV52 (23%, 287/1262), HPV16 (19%, 242/
1262), and HPV53 (13%, 169/1262) were most commonly
detected while HPV45 (10%, 131/1262) and HPV18 (9%, 109/
1262) were less often found (Table S1). The prevalence of viruses
with close genetic similarity to HPV16 and HPV18 was high
(Table S2). Specifically, 35% (445/1262) of men tested positive for
a-7 (HPV18, 39, 45, 59, 68, 70) and 41% (510/1262) tested
positive for a-9 (HPV16, 31, 33, 35, 52, 58) phylogenetically-
related viruses (Table S2). LrHPVs were detected commonly:
HPV6 (16%, 203/1262), followed by HPV61 (14%, 170/1262)
and HPV62 (13%, 163/1262) (Table S1). However, only 28%
(355/1262) of men tested positive for viruses genetically related to
HPV6 or HPV11, a-10 HPV types (HPV6, 11, 44, 55, 74) (Tables
S1 & S2).
Group 1 hrHPVs and lrHPVs were detected most often, while
Group 2 hrHPVs were less commonly found: 56% (702/1262),
61% (767/1262), and 35% (441/1262), respectively (Table S1).
Nearly 20% (250/1262) of men tested positive for a single HPV
type, most of which were lrHPVs (Table 2). Additionally, 75%
(755/1005) of HPV-infected men tested positive for multiple
individual HPV types (multi-type infections), 86% (649/755) of
whom tested positive for viruses from .1 IARC-risk category
(multi-risk-group infections) (Table 2). HIV-uninfected men tested
positive for a solitary HPV 1.8-times more often than HIV-
infected men: 25% (167/683) vs. 14% (83/579) (Table 2). The
prevalence of simultaneous infection by one or more Group 1
hrHPVs and lrHPVs was greater for HIV-infected than –
uninfected men: 62% (327/525) versus 38% (184/480), respec-
tively (p,0.05, Table 2). Group 2 hrHPVs were detected
infrequently among HPV-infected men in comparison to Group
1 hrHPVs and lrHPVs, both in single-type infections (4% (40/
1005), versus 8% (76/1005), and 13% (134/1005), respectively)
and as multi-type, single-risk-group infections (,1% (7/1005)
versus 5% (51/1005) and 5% (48/1005), respectively). Group 2
infections found in multi-type, multi-risk-group infections were
predominantly in combination with both Group 1 hrHPVs and
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Table 1. Sociodemographic Characteristics, Sexual Behavior Characteristics, HIV, and Human papillomavirus (HPV) infection
Characteristics of 1262 Multicenter AIDS Cohort Study Participants Evaluated for HPV DNA using Anal Swab Specimens.
HIV Seropositive HIV Seronegative Total
(N = 579) (N = 683) (N = 1262)
n (%) n (%) n (%)
Characteristic
Age (years)
,30 4 (01) 9 (01) 13 (01)
30–39 31 (05) 34 (05) 65 (05)
40–49 154 (27) 108 (16) 262 (21)
50–59 280 (48) 277 (41) 557 (44)
60–69 101 (17) 203 (30) 304 (24)
70–80 9 (02) 48 (07) 57 (05)
.80 0 (00) 4 (01) 4 (,1)
Racea
Black/African American 148 (25.6) 70 (10.3) 218 (17.3)
Caucasian/White 405 (70.0) 588 (86.1) 993 (78.7)
Asian 3 (,1.0) 7 (01.0) 10 (,1.0)
Other 23 (04.0) 18 (02.6) 41 (03.3)
Ethnicity
Hispanicb 56 (09.7) 44 (06.4) 100 (07.9)
Smoking
Ever Smoked MACS Visit 1 to 24 months before HPV testing
Yes 427 (73.8) 486 (71.2) 913 (72.4)
No 152 (26.2) 197 (28.8) 349 (27.6)
Ever Smoked within last 24 months before HPV testing c
Yes 189 (32.6) 123 (18.0) 312 (24.7)
No 390 (67.4) 560 (82.0) 950 (75.3)
AIDS Defining Illnessesd
None 486 (83.9) – –
Kaposi’s Sarcoma 17 (02.9) – –
Pneumocystis Pneumonia 26 (04.5) – –
Non-Hodgkin’s Lymphoma 1 (00.2) – –
Wasting Syndrome 15 (02.6) – –
HPV-DNA Prevalence
None 54 (09.3) 203 (29.7) 257 (20.4)
$1 HPV Type 525 (90.7) 480 (70.3) 1005 (79.6)
IARC HPV Carcinogenicity Classification
Group 1, strong carcinogens 396 (68) 306 (45) 702 (56)
Group 2, weaker carcinogens 255 (44) 186 (27) 441 (35)
Lower Risk 445 (77) 322 (47) 767 (61)
HPV 16 or 18 180 (31.1) 139 (20.4) 319 (25.3)
HPV 16 133 (23.0) 109 (15.9) 242 (19.2)
HPV 18 69 (11.9) 40 (05.9) 109 (08.6)
Seropositive Seronegative Total
Characteristic Mean (SD) Median Mean (SD) Median Mean (SD) Median
Number Sexual Partnerships Reported
Lifetime Total at first MACS Visit e 302.(100) 100 244.(90) 90.0 270 (488) 100
MACS Visit 1–24 Months Before the HPV Test Visit f 229 (504) 89 200 (351) 82 213 (428) 84
Anal HPV Infection Characteristics in MSM
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lrHPVs (39%, 255/649), and seldom detected exclusively with
Group 1 (10%, 64/649) or lrHPVs (11%, 74/649), alone (Table 2).
LrHPVs were detected very often, overall, whether in single-type
infections (54%, 134/250), in multi-type, single-risk-group infec-
tions (45%, 48/106), or in multi-type, multi-risk-group infections
(90%, 585/649; Table 2). Multiple-risk-group, multi-type Group
1, 2, and lower-risk HPV infections were more prevalent among
HIV-infected than –uninfected men: 44% (173/398) versus 33%
(83/251) (p,0.05, Table 2).
Age and HPV infections. Anal HPV prevalence estimates
were high across the age spectrum (Figure 1A). For men 40 years
and older, lrHPV prevalence was highest overall (Figure 1A).
For example, 40–69 year old HIV-infected men tested positive
for Group 1, 2, and lower-risk HPVs more often than
HIV–uninfected men (Figure 1B–D). HIV-infected men as young
as 30 years tested positive for Group 1 hrHPVs and lrHPVs more
often than HIV-uninfected men (Figure 1D).
HIV-infection characteristics, some sexual behaviors, race
and some smoking characteristics only modestly affected the
Table 2. HPV-Infection Characteristics Among 1005 MACS MSM Showing One or More HPVs for Single and Multiply Detected HPV-
Types.
HIV seropositive
(N = 579)
HIV seronegative
(N = 683) Total
All Men
None 54 (09.3) 203 (29.7) 257 (20.4)
$1 HPV Type 525 (90.7) 480 (70.3) 1005 (79.6)
HPV-DNA Positive Men Only
(N = 525) n (%) (N = 480) n (%) (N = 1005) n (%)
Single HPV Detecteda 83 (15.8) 167 (34.8) 250 (24.9)
Group 1 22 (26.5) 54 (32.3) 76 (31.4)
Group 2 9 (10.8) 31 (18.6) 40 (16.0)
Low-riska 52 (62.7) 82 (49.1) 134 (53.6)
Multiple HPVs Detecteda 442 (84.2) 313 (65.2) 755 (75.1)
Single HPV Risk-Groupa 44 (10.0) 62 (19.8) 106 (14.0)
Group 1 20 (45.5) 31 (50.0) 51 (48.1)
Group 2 2 (04.5) 5 (08.1) 7 (06.6)
Low-risk 22 (50.0) 26 (41.9) 48 (45.3)
2–3 HPV Risk-Groupsa 398 (90.0) 251 (80.2) 649 (86.0)
Group 1 and Group 2a 27 (06.8) 37 (14.7) 64 (09.9)
Group 1 and Low-risk 154 (38.7) 101 (40.2) 255 (39.3)
Group 2 and Low-risk 44 (11.1) 30 (12.0) 74 (11.4)
Group 1, 2, and Low riska 173 (43.5) 83 (33.1) 256 (39.4)
ap,0.05 Comparing prevalence of infection for HIV+ to HIV-negative men.
doi:10.1371/journal.pone.0079492.t002
Table 1. Cont.
Seropositive Seronegative Total
Characteristic Mean (SD) Median Mean (SD) Median Mean (SD) Median
Number of Receptive Anal Intercourse Sexual Partnerships Reported
During the Last 24 Months Before the HPV Test Visit g 6.1 (19.3) 1 2.9 (7.6) 0 4.4 (14.3) 0
CD4 T-Cell Characteristics
CD4 cell count (cells/mm3) 609.(282) 583 929.(310) 900.0 782.(338) 737
Nadir CD4+ T-cell count (cells/mm3) 258 (159) 249 – – – –
Other HIV-infection Characteristics
HIV-infection Duration (years) 17.8 (7.6) 18.6 – – – –
Duration CART Use (years) 10.3 (4.4) 12.1 – – – –
Percent of Visits with HIV mRNA ,50 copies/mL (%) 52.7 (29.4) 52.9 – – – –
ap,0.001, bp=0.037, cp,0.001, dcategories are not mutually exclusive, ep=0.062; fp= 0.138 gp,0.001. P-values for comparing HIV+ vs. HIV- were by the Fisher exact
test or the Wilcoxon nonparametric test, as appropriate.
doi:10.1371/journal.pone.0079492.t001
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prevalence of Group 1 and 2 hrHPVs and lrHPVs. However,
White men showed 1.3-fold lower prevalence of Group 2 HPVs
than did minority men (p,0.01) and self-report for tobacco
smoking between Visit 1 and the study visit 24 months before
HPV testing was positively associated with the prevalence of
Group 2 hrHPVs and lrHPVs (PR = 1.21, p = 0.04, PR = 1.10
p = 0.05). Among HIV-infected men alone, bivariate analyses
suggested men with ,500 CD4+ cells/mm3, a higher lifetime
number of sexual partners, and the number of RAI partners
during the last 24 months of observation were positively associated
with the prevalence of Group 1 hrHPVs (PR: 1.14–1.23, p-values
,0.01–0.04). Only CD4+ cell count at the HPV test visit, the
number of sex partners and RAI partnerships reported for Visit 1
to the visit 24 months before testing and during the last 24 months,
respectively, positively affected Group 2 HPV prevalence estimates
(PR: 1.2–1.5, p-values: ,0.001–0.02). Men who reported com-
plete adherence to CART during the 4 days preceding the HPV-
test visit showed lower prevalence of Group 1 hrHPVs (PR = 0.84,
p,0.01). Every 10% increase in the total number of HIV+ study
visits where HIV-load measured ,50 copies/mL was protective
for Group 1 and Group 2 hrHPVs, alone in the bivariate analyses,
i.e., PR = 0.98, p = 0.03 and PR = 0.89, p,0.0001, respectively.
Multivariate Analyses
In separate multivariate analyses for Groups 1, 2 and lower-risk
HPVs, data for all men showed that HIV-infection positively
affected the prevalence of HPVs detected in anal cytology
specimens at all levels of CD4+ cell count (Figure 2). Specifically,
the prevalence of Group 1, 2 and lower-risk HPVs was 35–92%
higher for HIV-infected men with .500, 350–500 and ,350
CD4+ cells/mm3 when compared to HIV-uninfected men (p-
values,0.002, Figure 2). Also, Group 2 hrHPV prevalence alone
was 1.2-fold higher for men reporting ever smoking between the
first MACS visit and the visit 24 months before HPV testing;
conversely, White men also showed nearly 1.3-fold lower
prevalence of Group 2 hrHPVs than non-whites (Figure 2).
Compared to men enrolled after 2001, those enrolled earlier
showed 22% (95% CI: 5%, 41%) higher prevalence for Group 1
hrHPVs (p,0.05) alone (Figure 2). Also, the number of sexual
partnerships reported across the risk period only modestly
influenced the prevalence of HPV infections (Table S3). For
example, the prevalence of Group 1, 2 and lower-risk HPVs was
17–35%, on average, for men reporting $4 RAI partners over the
24 months preceding HPV testing (p-values,0.005, Table S3).
Men reporting $30 lifetime sex partners at their first MACS visit
showed 17–24% higher prevalence of lrHPVs than men reporting
fewer (Table S3, p-values,0.03). Last, the adjusted analyses
showed age, self-report for smoking in the 24 months prior to HPV
testing, and study site did not influence prevalence of Group 1, 2
or lower-risk HPVs (p-values.0.05).
Multivariate analyses limited to HIV-infected men alone
showed adherence to CART treatment, higher CD4+ cell count,
Figure 1. A–D: Age-specific Prevalence of Group 1 and 2 High-risk HPVs and Lower-risk HPVs for 1262 Men Enrolled in the
Multicenter AIDS Cohort Study Anal Health Sub-study. (A) Virus Type Group-specific Prevalence for All Men. (B–D) Comparison of 579 HIV-
infected and 683–Uninfected Men for (B) Group 1 High-risk HPVs, (C) Group 2 High-risk HPVs, and (D) Lower-risk HPVs.
doi:10.1371/journal.pone.0079492.g001
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and higher proportion of study visits with low HIV-load were
statistically significantly associated with the prevalence of Group 1,
2 or lrHPV infections (Figure 3). Specifically, the prevalence of
Groups 1 and 2 hrHPVs was 2–5% lower for every 10% increase
in the number of HIV+ study visits where HIV-load measured
,50 copies mRNA/mL (Figure 3). Men reporting complete
adherence to CART for the four days preceding the study visit
showed 16% lower prevalence of Group 1 hrHPVs, alone, in
comparison to less adherent men: PR = 0.86 (0.76, 0.97) (Figure 2).
Additionally, the prevalence of Group 1 hrHPVs alone was 17%
higher for men showing 350–500 CD4+ cells/mm3, compared to
men with .500 T-lymphocytes/mm3 (p = 0.01, Figure 2). Among
HIV-infected men, sexual partnerships again affected prevalence
of all virus groupings modestly. Although prevalence of Group1
hrHPVs and lrHPVs was unaffected, the prevalence of Group 2
hrHPVs alone was nearly 1.4 higher for men reporting $4 RAI
partners during the 24 months before HPV testing than men
reporting none (Table S4). Lifetime number of sexual partners
only affected the prevalence of lrHPVs, albeit modestly, with men
reporting $30 partners showing 14–18% higher prevalence of
infection over men reporting ,30 partners (p-values ,0.05 for 1
of 3 comparisons; Table S4). Age, race, enrollment period, total
HIV-infection duration, years of CART use, tobacco smoking,
and study site did not influence prevalence estimates for Group 1,
2 or lower-risk HPVs in the multivariate adjusted analyses (p-
values.0.05).
Discussion
This study demonstrates that HPV infections are common, and
are associated with age and HIV-infection. Specifically, HIV-
infected men 40–69 years of age are at higher risk for Group 1, 2
and lower-risk HPVs than –uninfected men. However, among the
youngest and oldest men evaluated, we observed no statistically
significant differences. Expectedly, our data suggest HPV infection
prevalence is high among young adult MSM, largely irrespective
of HIV-serostatus. These findings are consistent with reports by
others that suggest the prevalence of any anal HPV infection
among HIV-infected MSM may range from 30% to .90% [32–
35]. However, some reports suggest the prevalence of anal HPV
infections for men who have sex with women may range from 0–
33%, compared to studies that show prevalence estimates as high
as 68% among HIV-infected MSM [20,21,36–38].
Most important, the prevalence of strongly and weakly
carcinogenic HPVs is unequal among HIV-infected and -
uninfected men. The prevalence of anal Group 1 hrHPVs and
lrHPVs were similarly high across the age spectrum, while Group
2 hrHPVs were detected less frequently. Comparatively, preva-
lence estimates for a large sample of HIV-uninfected U.S. MSM
showed a similar flat, albeit lower, age-specific prevalence of lr-
and hrHPVs than reported herein [23]. Global age-
specific prevalence patterns for women differ sharply, with peak
prevalence estimates among females under 25, diminishing
thereafter through their early 40 s, from ,20% to ,10%, overall,
with some regional variation [5]. However, one tri-national study
Figure 2. Comparison of Prevalence Ratios for Group 1 and 2 High-risk and Lower-risk HPVs for 1262 Men Group 1 and 2 High-risk
HPVs and Lower-risk HPVs for 1262 Men Enrolled in the Multicenter AIDS Cohort Study Anal Health Sub-study.a
doi:10.1371/journal.pone.0079492.g002
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of 176 MSM reported an inverse association between age and anal
HPV-prevalence, overall (,60% to ,40%), and for hrHPVs
(,40% to ,20%) over a similar age span [24].
Finding a high prevalence of Group 1 hrHPVs in anal
specimens from HIV-infected MSM is important for cancer
prevention strategies. A recent report shows HIV-infected anal
cancer cases evidence 2.3–4.5 times higher odds than matched
control for detecting anti-HPV16, 18, 31, 33, 35, 45, 52 or 58 L1
antibodies (p-values:,0.05) in serum, all Group 1 hrHPVs [39]. In
addition, the temporal analyses of these Swiss HIV Cohort data
show anal cancer cases evidenced 5.9–14–fold (p-values:# 0.05)
higher odds of showing ,350 CD4+ cells/mm3 as early as 6–7
years before diagnosis than did age-, region-, and transmission
mode-matched controls, but no statistically significant higher odds
related to HIV-load [39]. Consistent to these reports, our data
show HIV-load ,50 copies/mL protects against Group 1 and 2
hrHPV infections and that complete adherence to CART protects
against Group 1 hrHPVs, as well. Important to our findings,
experts conclude that even moderate HIV-related immune
suppression measured as many as 6–7 years before an anal cancer
diagnosis suggest that better HIV-treatment adherence may
decrease risk for persistent Group 1 hrHPV infections that likely
cause most anal cancers [40].
Figure 3. Comparison of Prevalence Ratios for Group 1 and 2 High-risk and Lower-risk HPVs for 579 HIV-infected Men Enrolled in
the Multicenter AIDS Cohort Study Anal Health Sub-study.a
doi:10.1371/journal.pone.0079492.g003
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Our findings showed that the prevalence of Group 2 hrHPVs
was lower among Whites than non-Whites, suggesting that sexual
network characteristics may vary by race. To date, we find no
studies that evaluated the prevalence of these possible-probable
weaker carcinogens separately from strongly carcinogenic
hrHPVs. Generally, published data for women suggest that
prevalence of HPV-infections varies geographically, among those
with normal and abnormal cytology and for related cancers [5,41–
43]. Few data [44] suggest that HPV-infection prevalence within
geographic regions varies by race [41–43]. Neither Nyitray et al.
or Chin-Hong and colleagues report an effect of race in their
multivariate analyses [23,24]. These high prevalence trends,
especially among older MSM, are important for cancer preven-
tion, surveillance, and program planning. The proportion of anal
cancer cases who are infected with HIV has risen dramatically and
the age at diagnosis among HIV-infected men may be trending
younger since the introduction of effective antiretroviral therapies
for HIV infection [45,46]. Thus, our finding that Group 2 HPV
prevalence was less common among Whites than men of other
races suggests it is important to monitor type-specific trends in
HPV-related anal cancers as infection with Group 2 carcinogenic
HPVs may differ by race.
Tobacco smoking is long associated with uterine cervical HPV-
infections and –related cancers in women [47,48]; however,
recently published findings are mixed for anal HPV infections. For
example, adult HIV-infected anal cancer cases show 2.6-fold
higher odds of current tobacco use when compared to matched
controls [39]. Nielson et al., reported current tobacco users
showed 2.1-fold higher odds (p,0.05) than never smokers for
detecting any hrHPV on external genital or internal anal surfaces
[49]; in contrast, we found higher risk for detection of Group 2
hrHPVs alone when smokers and non-smokers were compared.
However, Nyitray et al., report the odds of detecting any HPVs
and hrHPVs among HIV-uninfected MSM may be mixed: 1.2
and 0.8 (p.0.05) respectively [24].
These analyses may be limited. Few very young and few men
over 70 years old may limit our comparisons for age-specific
infection prevalence, and incident and persistent infections cannot
be discerned using cross-sectional data. While the assay detected
all Group 1 hrHPVs, we were unable to evaluate four Group 2
hrHPVs (i.e., HPV30, 34, 85, and 97) [14]. Also, MACS data
cannot discriminate between men reporting the same partner at
every visit from men reporting a new single sex partner at each
study visit. While most variables analyzed herein were informed
objective criteria and laboratory tests, some relied upon self-report
data that may be misreported, especially where topics are socially
sensitive. The direction of bias introduced by misclassified
polychotomous or interrelated variables may be unpredictable
[50,51]. Last, passage of a sterile Dacron swab through the anal
verge cannot completely discriminate between HPVs on external
anogenital surfaces and intra-anal infections alone.
The prevalence of high-risk Group 1 HPVs, that include
HPV16, may explain escalating IAC rates among HIV-infected
men over the past decade [1,2,12,39]. Our analyses support
strategies that seek to increase HIV-medication compliance and
promote lower HIV-load characteristics among HIV-infected
MSM so as to lower risk for most hrHPVs, even if the reduction is
modest. Also, our data support prevention messages that promote
safe-sex practices, including long-term mutual monogamy and
condom use to prevent exposure to new hrHPVs. Last, the high
prevalence of multi-type and multi-group HPV infections in these
men warrants further study to determine whether HIV and multi-
type HPV infections synergistically act to increase anal cancer risk.
Overall, our analyses warrant careful surveillance for Group 1 and
2 HPVs using tumor registry data and ongoing longitudinal studies
of high-risk MSM.
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